PDS Biotechnology (PDSB)
(Delayed Data from NSDQ)
$3.54 USD
-0.06 (-1.53%)
Updated May 14, 2024 04:00 PM ET
After-Market: $3.54 +0.01 (0.14%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PDSB 3.54 -0.06(-1.53%)
Will PDSB be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PDSB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PDSB
All You Need to Know About PDS Biotechnology (PDSB) Rating Upgrade to Buy
PDS Biotech's (PDSB) Shares Up 12% in a Month: Here's Why
PDSB: What are Zacks experts saying now?
Zacks Private Portfolio Services
PDS Biotech (PDSB) Up 32% on Interim Data From HPV Cancer Study
PDS Biotech (PDSB) Completes Enrollment for HPV Cancer Study
PDS Biotech (PDSB) Up on Data From HPV-Positive Cancer Study
Other News for PDSB
Notable earnings before Wednesday's open
IN BRIEF: NetScientific says PDS Biotech's Versamune meets endpoints
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
PDS Biotech to Participate in Upcoming May 2024 Investor Conferences
Buy Rating Affirmed for PDS Biotechnology on Promising Clinical Data and Strategic Focus